# A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

> **NCT00771251** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 311 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CNTO 148
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00771251
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2015-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771251, "A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00771251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*